Abstract:Background The concentrations of linezolid, its optimal regimen and the associated side effects in elderly patients remain unclear.Methods In this multicentre, prospective study, elderly patients receiving linezolid at four tertiary hospitals in Beijing between May 2021 and December 2022 were included. Linezolid concentrations and haematological toxicity were monitored dynamically. Risk factors for linezolid overexposure and moderate-to-severe linezolid-induced thrombocytopenia (M/S LIT) were analysed, and a predictive model of M/S LIT was developed.Results A total of 860 linezolid concentrations were measured in 313 patients. The median trough concentrations of linezolid were 24.4 (15.3, 35.8) mg/L at 36-72 h and 26.1 (17.0, 38.1) mg/L at 5-10 days (P = 0.132). Severe linezolid exposure was independently associated with age, estimated glomerular filtration rate (eGFR) and the worst SOFA score (SOFA1), and we further recommended dose regimens for elderly patients based on these findings. The incidences of linezolid-induced thrombocytopenia(LIT) and M/S LIT were 73.5% and 47.6%, respectively. M/S LIT was independently correlated with treatment duration, average trough concentration (TDMa), baseline platelet count, eGFR and baseline SOFA score (SOFA0). The developed nomogram predicted M/S LIT with an area under the curve of 0.767 (95% CI 0.715-0.820), a sensitivity of 71.1% and a specificity of 73.2%.Conclusions Linezolid trough concentrations increased dramatically in the elderly, by about 10 mg/L in patients aged 65-80 years, followed by a further increase of 10 mg/L for every 10 years of age. Therapeutic drug monitoring is recommended in elderly patients receiving linezolid. The developed nomogram may predict M/S LIT and guide dosage adjustments of linezolid. Clinical trial registration number: ChiCTR2100045707Conclusions Linezolid trough concentrations increased dramatically in the elderly, by about 10 mg/L in patients aged 65-80 years, followed by a further increase of 10 mg/L for every 10 years of age. Therapeutic drug monitoring is recommended in elderly patients receiving linezolid. The developed nomogram may predict M/S LIT and guide dosage adjustments of linezolid. Clinical trial registration number: ChiCTR2100045707

Therapy drug monitoring of linezolid in serum of critically ill patients

Therapy Drug Monitoring of Linezolid in Serum of Critically Ⅲ Patients

Determination of serum linezolid concentration in critically ill patients during continuous veno-venous hemofiltration

HPLC determination and clinical application of linezolid concentration in human serum

Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients.

Concentration Determination of Linezolid in Human Serum of Patients with Severe Infections and Evaluation of Clinical Application

Therapeutic drug monitoring of linezolid: HPLC-based assays for routine quantification of linezolid in human serum and cerebrospinal fluid

Clinical Efficacy and Safety of Linezolid in Intensive Care Unit Patients

High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid

Linezolid Pharmacokinetics in Critically Ill Patients: Continuous versus Intermittent Infusion

Model Based Identification of Linezolid Exposure–toxicity Thresholds in Hospitalized Patients

Therapeutic Drug Monitoring and Receiver Operating Characteristic Curve Prediction May Reduce the Development of Linezolid-Associated Thrombocytopenia in Critically Ill Patients

Optimizing the dosing regimens of linezolid against gram-positive cocci in critically ill patients with different renal functions: a Monte Carlo simulation

Pharmacokinetic/pharmacodynamic evaluation of linezolid for the treatment of staphylococcal infections in critically ill patients

A Systematic Review of Linezolid Pharmacokinetics/Pharmacodynamics in Patients Undergoing Continuous Renal Replacement Therapy: Does One Size Fit All?

Pharmacokinetics and Pharmacodynamics of Linezolid in Patients with Sepsis Receiving Continuous Venovenous Hemofiltration and Extended Daily Hemofiltration

Simultaneous Determination of Linezolid and Voriconazole Serum Concentrations Using Liquid Chromatography-Tandem Mass Spectrometry

Therapeutic Drug Monitoring Can Improve Linezolid Dosing Regimens in Current Clinical Practice: A Review of Linezolid Pharmacokinetics and Pharmacodynamics

Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: Influence of residual renal function on PK/PD target attainment

Expert consensus statement on therapeutic drug monitoring and individualization of linezolid

Therapeutic Drug Monitoring of Linezolid and Exploring Optimal Regimens and a Toxicity-Related Nomogram in Elderly Patients: a Multicentre, Prospective, Non-Interventional Study.